Parecoxib
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Intravenous, intramuscular |
ATC code | |
Legal status | |
Legal status | |
Elimination half-life | 22 minutes (parecoxib) 8 hours (valdecoxib) |
Excretion | Kidney (70%, metabolites) |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Parecoxib, sold under the brand name Dynastat among others, is a water-soluble and
It was patented in 1996 and approved for medical use in 2002.[3]
Approval
In 2005, the US
All anti-inflammatory medications in the US carry the same warning regarding skin reactions, and none are approved for use during CABG surgery, so the reason for the FDA denying the approval of parecoxib remains unknown, but was likely related to political pressure from the US Congress to not approve another
The political motivation to not approve parecoxib was further supported by a 2017 pooled analysis of safety data in 28 published studies, which showed after 69,567,300 units of parecoxib, skin rash and cardiac complications were minimal, if at all, different from placebo.[7]
Parecoxib, along with other COX-2 selective inhibitors, celecoxib, valdecoxib, and mavacoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[8][9]
Parecoxib is the first parenteral COX-2 selective inhibitor available for clinical use in pain management. Its first perceptible analgesic effect occurs within seven to thirteen minutes, with clinically meaningful analgesia demonstrated within twenty-three to thirty-nine minutes and a peak effect within two hours following administration of single doses of 40 mg by IV or IM injection.[10]
See also
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ "Dynastat EPAR". European Medicines Agency. 22 March 2002. Retrieved 2 January 2024.
- ISBN 9783527607495.
- ^ Health "Association of Bextra (Valdecoxib) with Serious Adverse Drug Reactions". Health Canada. April 21, 2005.
- PMID 17305567.
- ^ Kiehl S (March 13, 2005). "Secrecy on the Rise". The Baltimore Sun.
- PMID 29066931.
- ^ Langreth R (June 23, 2003). "The Chemical Cobbler". Forbes.
- ^ "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018.
- PMID 33155461.
Further reading
- Villasís-Keever MA, Rendón-Macías ME, Escamilla-Núñez A (2009). "[Systematic review to assess the effectiveness and safety of parecoxib]". Acta Ortopedica Mexicana (in European Spanish). 23 (6): 342–50. PMID 20377000.
- Lloyd R, Derry S, Moore RA, McQuay HJ (April 2009). "Intravenous or intramuscular parecoxib for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews. 2019 (2): CD004771. PMID 19370610.